Oncopeptides announces that PEPAXTO (melphalan flufenamide) has been included in the new Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network (NCCN) in Oncology.
PEPAXTO, in combination with dexamethasone, was granted accelerated approval by the FDA on February 26, 2021, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
“The NCCN Guidelines are a trusted resource for clinicians in the management of oncology patients,” says Marty J Duvall, Chief Executive Officer at Oncopeptides. “We are grateful that melphalan flufenamide is included in these guidelines and believe that they will facilitate the management of previously treated multiple myeloma patients, who need additional treatment options”.
NCCN is an alliance of 30 cancer centers in the United States. Over the past 25 years, NCCN has developed an integrated suite of tools to improve the quality of cancer care. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes.
Photo of Marty Duvall: Oncopeptides